Evidence map›Paper›PMID 20082461›Full record

ArticleAmerican journal of medical genetics. Part A2010

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Joseph L Kissil, Jaishri O Blakeley, Rosalie E Ferner, Susan M Huson, Michel Kalamarides, Victor-Felix Mautner, Frank McCormick, Helen Morrison, Roger Packer, Vijaya Ramesh and 5 more

Registry-linked trialAbstract readConference Proceedings
In one paragraph

Article in American journal of medical genetics. Part A, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03231306 (A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03231306 phase2completednot on this mapstarted 2017, after this paper: background citation

A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2017 to 2024Enrolled45ConditionsNeurofibromatosis Type 1, Plexiform NeurofibromaArmsBinimetinib
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.Journal of neurological surgery. Part B, Skull base · 2012
    Article
  7. Article
  8. Article
  9. Therapeutics for childhood neurofibromatosis type 1 and type 2.Current treatment options in neurology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joseph L KissilThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Jaishri O Blakeley
Rosalie E Ferner
Susan M Huson
Michel Kalamarides
Victor-Felix Mautner
Frank McCormick
Helen Morrison
Roger Packer
Vijaya Ramesh
Nancy Ratner
Katherine A Rauen
David A Stevenson
Kim Hunter-Schaedle
Kathryn North

Funding

The Role of RAC1 in CancerR01CA124495 · NCI · WISTAR INSTITUTE · PI KISSIL, JOSEPH · 2009 to 2018
$3.9M
2009 NF ConferenceR13NS066550 · NINDS · CHILDREN'S TUMOR FOUNDATION · PI KISSIL, JOSEPH · 2009 to 2009
$52k
NCI NIH HHS R01 CA124495NINDS NIH HHS 1R13NS066550-01NINDS NIH HHS R13 NS066550
6 · The paper itself

Abstract

The NF Conference is the largest annual gathering of researchers and clinicians focused on neurofibromatosis and has been convened by the Children's Tumor Foundation for over 20 years. The 2009 NF Conference was held in Portland, Oregon from June 13 to June 16, 2009 and co-chaired by Kathryn North from the University of Sydney and The Children's Hospital at Westmead, Sydney, Australia; and Joseph Kissil from the Wistar Institute, Philadelphia. The Conference included 80 platform presentations in 9 sessions over 4 days; over 100 abstracts presented as posters; and three Keynote presentations. To date, there have been tremendous advances in basic research in the pathogenesis of neurofibromatosis, and more recently in progress toward identifying effective drug therapies and the commencement of neurofibromatosis clinical trials. The NF Conference attendees have significantly increased (doubling from 140 in 2005 to 280 attending in 2009) with a significant increase in attendance of physicians and clinical researchers. Correspondingly the NF Conference scope has expanded to include translational research, clinical trials and clinical management issues while retaining a core of basic research. These themes are reflected in the highlights from the 2009 NF Conference presented here.

Indexed as

AnimalsChildClinical Trials as TopicCognition DisordersDisease Models, AnimalGenotypeHumansMiceNervous System NeoplasmsNeurofibromatosis 1Neurofibromatosis 2PhenotypeSignal Transduction

Identifiers

PMID20082461
PMCPMC2818482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.